

In the Claims

Please amend the claims to read as follows:

Please cancel claims 34-103 without prejudice or disclaimer.

Please cancel claim 115 without prejudice or disclaimer.

Please cancel claims 117-171 without prejudice or disclaimer.

1-103. (canceled)

104. (currently amended) A method for treating a subject having a tumor, comprising:
administering to a vertebrate subject having a tumor an oligonucleotide 10-50 nucleotides
long comprising the sequence:

~~N₁-N₂-G-N₃-G~~

~~wherein N₁ represents any nucleotide if N₂ and N₃ are G; N₂ represents any nucleotide if
N₁ and N₃ are G; and N₃ represents any nucleotide if N₁ and N₂ are G, wherein at least two of N₁,
N₂, and N₃ are G a sequence chosen from GGGGG, GAGGG, GGGAG, GTGGG, and GGGTG,~~
wherein the oligonucleotide does not comprise a CG dinucleotide, in order to treat the subject.

105. (previously presented) The method of claim 104, wherein the oligonucleotide is DNA.

106. (previously presented) The method of claim 104, wherein the oligonucleotide is RNA.

107. (previously presented) The method of claim 104, wherein at least one nucleotide of the
oligonucleotide is replaced by a corresponding nucleotide analog or derivative.

108. (previously presented) The method of claim 104, wherein at least one nucleotide of the
sequence is replaced by a corresponding nucleotide analog or derivative.

109. (previously presented) The method of claim 104, wherein at least two nucleotides of the oligonucleotide are linked by a nuclease-resistant bond.

110. (previously presented) The method of claim 109, wherein the nuclease-resistant bond is selected from the group consisting of phosphorothioate, methylphosphonate, and peptide bonds.

111. (canceled)

112. (previously presented) The method of claim 104, wherein the oligonucleotide is 13-30 nucleotides long.

113. (previously presented) The method of claim 104, wherein the oligonucleotide is 17-21 nucleotides long.

114. (previously presented) The method of claim 104, wherein the sequence represents the 3' terminus of the oligonucleotide.

115. (canceled)

116. (previously presented) The method of claim 104, further comprising administering a tumor-specific antigen.

Claims 117-171 (canceled)